Clinical Trials Logo

Clinical Trial Summary

The purpose of the study was to assess efficacy, tolerability, safety and pharmacokinetics of Romidepsin in subjects with progressive or relapsed peripheral T-cell lymphoma


Clinical Trial Description

This is a Phase 1/2, non-randomized, open-label, single-arm trial with two phases. The first phase is a 3 + 3 dose escalation phase to determine a recommended dose for treating patients with Peripheral T-Cell Lymphoma (PTCL) or Cutaneous T-Cell Lymphoma (CTCL) based on the assessment of Dose Limiting Toxicities (DLTs).The second phase will assess efficacy at the recommended dose by measuring objective response [Complete Response (CR), Unconfirmed Complete Response (CR(u)) or Partial Response (PR)] and determining best overall response of each patient. Phase 1 will enroll a maximum of 12 patients and Phase 2 will enroll up to approximately 40 patients ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01456039
Study type Interventional
Source Celgene
Contact
Status Completed
Phase Phase 1/Phase 2
Start date December 1, 2011
Completion date December 14, 2018

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03547700 - Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL) Phase 1/Phase 2
Completed NCT02788916 - A Retrospective Study of Clinical, Phenotypic and Genetic Factors of Peripheral T-Cell Lymphomas N/A
Completed NCT02567656 - Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma Phase 1
Completed NCT01142674 - T-Cell Project: Prospective Collection of Data in Patients With Peripheral T-Cell Lymphoma
Withdrawn NCT03355768 - Romidepsin Versus Combination of Romidepsin Plus Pralatrexate in PTCL Phase 3
Not yet recruiting NCT05006664 - Brentuximab Vedotin in Combination With CHEP in Patient With PTCL Phase 2
Terminated NCT00514722 - Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced Hematopoietic Malignancies N/A
Completed NCT01679860 - Intensive Chemo-immunotherapy as First Line Treatment in Adult Patients With Peripheral T- Cell Lymphoma Phase 2
Recruiting NCT06254495 - A Safety Study of SGN-35C in Adults With Advanced Cancers Phase 1
Completed NCT05137847 - A Study of Remitoro in Participants With Recurrent or Refractory Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma (All Case Study)
Terminated NCT03601819 - Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders Phase 1
Completed NCT03049449 - T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas Phase 1
Completed NCT00211185 - A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma Phase 2
Not yet recruiting NCT03051581 - 18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Peripheral T-cell Lymphoma N/A
Not yet recruiting NCT03051568 - Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Peripheral T-cell Lymphoma N/A
Completed NCT00646854 - Alemtuzumab and CHOP in T-cell Lymphoma Phase 3
Terminated NCT02535247 - Study of MK-3475 Alone or in Combination With Copanlisib in Relapsed or Refractory NK and T-cell Non-Hodgkin Lymphoma Phase 1/Phase 2
Recruiting NCT02364466 - Cohort of Peripheral T Cell Lymphoma N/A
Recruiting NCT02404571 - GDP in Frontline Chemotherapy for Patients With PTCL-NOS Phase 2
Completed NCT03742921 - ISTODAX® for Intravenous Infusion Drug Use Results Survey- Relapsed or Refractory Peripheral T-Cell Lymphoma